• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic delivery >Dexamethasone intravitreal implant (OZURDEX?) for macular edema secondary to noninfectious uveitis: a review of the literature
【24h】

Dexamethasone intravitreal implant (OZURDEX?) for macular edema secondary to noninfectious uveitis: a review of the literature

机译：地塞米松intraviteal植入物（Ozurdex？）用于次缺血性葡萄膜炎的黄斑水肿：对文献的综述

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Macular edema (ME) is the leading cause of visual loss in uveitis and may persist long after ocular inflammation has been resolved. Local steroids are the first line treatment for uveitis and uveitic ME. Dexamethasone intravitreal implant (OZURDEX?; Allergan, Inc., CA, USA) has been used to treat diabetic ME and ME secondary to retinal vein occlusion. Recent studies have also demonstrated that Ozurdex may be effective treatment for patients with persistent uveitic ME. In this review, we present the results of the real word studies concerning the efficacy and safety of Ozurdex for the treatment of uveitic ME. With the term ‘uveitis’ we mean a group of diseases which consists of many different disorders with a variety of causes; however, the etiology of most of them remains unknown. Uveitis is one of the five leading causes of visual impairment and blindness in the developed world and responsible for about 20% of legal blindness, also affecting younger patients. It is the inflammation of the uveal tract, the vascular layer between the sclera and the neuroretina, which consists posteriorly of the choroid, in the middle part of the ciliary body and anteriorly of the iris. Uveitis can be classified into anterior, intermediate, posterior and panuveitis according to the primary location of the inflammation. The term macular edema’ (ME) is used to describe the retinal thickening in the macular area caused by the breakdown of the blood-retinal barrier leading to accumulation of extracellular fluid in the intraretinal area and in the subretinal space. Uveitic ME (UME) is the main cause of visual loss in uveitis, resulting in reduced visual acuity (VA) <20/40 in about 33% of posterior uveitis cases. Panuveitis and intermediate uveitis are also significantly associated with UME, with an incidence of 66 and 65%, respectively.
机译：黄斑水肿（ME）是葡萄膜炎视觉损失的主要原因，并且在发现眼部炎症后可能持续存在。局部类固醇是葡萄炎和uveitic Me的第一线治疗方法。地塞米松intraviteal植入物（Ozurdex ?;; Allergan，Inc.，CA，USA）已被用来治疗糖尿病Me和Me继发于视网膜静脉闭塞。最近的研究还表明，Ozurdex可能有效治疗持续的Uveitic Me患者。在这篇综述中，我们介绍了关于Ozurdex治疗uveitic Me的疗效和安全性的真实单词研究结果。术语“葡萄膜炎”，我们的意思是一组疾病，这些疾病由许多不同的疾病组成，具有各种原因;然而，大多数人的病因仍然未知。葡萄膜炎是发达国家视力障碍和失明的五个主要原因之一，负责约20％的法律失明，也影响了年轻患者。它是UVEAL道的炎症，巩膜和神经植物之间的血管层，其在脉络膜后部和睫状体中间部分和虹膜前面组成。根据炎症的主要位置，葡萄膜炎可以分为前部，中间，后和引导性炎。术语黄斑水肿'（ME）用于描述由于血管视网膜屏障的崩溃引起的黄斑区域中的视网膜增厚，导致在内特里地区和超靶空间中的细胞外液体积聚。 Umvitic Me（UME）是葡萄膜炎视力丧失的主要原因，导致视力减少（VA）<20/40，约33％的后葡萄蜂炎病例。引诱性和中间葡萄膜炎也与UME显着相关，分别发病66和65％。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号